Targeting clusterin induces apoptosis, reduces growth ability, invasion and mediates sensitivity to chemotherapy in human cancer in human osteosarcoma cells.
Secretory clusterin (sCLU) is a protein biosensor of oxidative stress and inflammation, which is involved in numerous physiological processes, such as carcinogenesis, tumor growth and tissue remodelling. sCLU is up-regulated in many cancers, which affects cell apoptosis and invasion. Overexpression of sCLU also confers treatment resistance to many varied anti-cancer therapies. Therefore sCLU could be an attractive target in cancer therapy. In the present study, we study the role of targeting sCLU using small interfering RNAs (siRNAs) on cell apoptosis, invasion and sensitivity to chemotherapy in human cancer in human osteosarcoma cells. Expression of sCLU in 98 cases of osteosarcoma was detected by immunohistochemistry. The sCLU levels in 98 cases and clinical data and survival was compared. siRNA-mediated sCLU gene silencing on cell apoptosis, viability , invasion and chemosensitivity to doxorubicin in osteosarcoma cells were detected. sCLU expression was found in 59 (60%) of the 98 patients. A positive correlation was observed between sCLU expression and metastatic disease (P = 0.036) and a negative correlation between sCLU expression and response to chemotherapy (P = 0.002). Targeting sCLU expression in osteosarcoma cells induces significant reduction of cellular growth and higher rates of spontaneous endogenous apoptosis. In addition, targeting sCLU expression inhibits invasion of osteosarcoma cells. Furthermore, targeting sCLU expression significantly sensitized to chemotherapeutic drugs doxorubicin. Overexpression of sCLU was significantly correlated with metastasis and chemosensitivity in osteosarcoma cells. The described sCLU-specific siRNA that can potently silence sCLU gene expression may thus prove valuable agents during antitumor therapy.